Get the Stockscreener App
0.9994
0.95%
0.0094
Pre-market:
1.00
0.0006
+0.06%
Predictive Oncology Inc stock is traded at $0.9994, with a volume of 150.76K.
It is up +0.95% in the last 24 hours and down -9.96% over the past month.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
See More
Previous Close:
$0.99
Open:
$0.9603
24h Volume:
150.76K
Relative Volume:
0.06
Market Cap:
$8.55M
Revenue:
$1.52M
Net Income/Loss:
$-13.97M
P/E Ratio:
-0.3277
EPS:
-3.05
Net Cash Flow:
$-13.29M
1W Performance:
+4.38%
1M Performance:
-9.96%
6M Performance:
+26.35%
1Y Performance:
-25.42%
1-Day Range:
$0.9603
$1.06
1-Week Range:
$0.90
$1.06
52-Week Range:
$0.55
$3.06
Predictive Oncology Inc Stock (POAI) Company Profile
Name
Predictive Oncology Inc
Sector
Industry
Phone
412-432-1500
Address
91 43RD STREET, PITTSBURGH, MN
Compare POAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
POAI
Predictive Oncology Inc
|
0.9994 | 8.55M | 1.52M | -13.97M | -13.29M | -3.05 |
|
ISRG
Intuitive Surgical Inc
|
522.41 | 199.98B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.72 | 48.99B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.58 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
251.36 | 36.65B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
31.40 | 15.38B | 11.89B | -560.00M | 191.00M | -1.10 |
Predictive Oncology Inc Stock (POAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
Predictive Oncology Inc Stock (POAI) Latest News
Predictive Oncology Faces Nasdaq Delisting Notice - TipRanks
Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Major AI Breakthrough in Cancer Research: Leading Pharma Companies Unite in Revolutionary Oncology Initiative - Stock Titan
SEC Form 424B5 filed by Predictive Oncology Inc. - Quantisnow
'It's not something you choose to do, it's something you have to do': CEO & artist shares story - WTAE
Predictive Oncology (NASDAQ:POAI) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Predictive Oncology to defend against Renovaro’s claims in court - Investing.com Australia
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Predictive Oncology (POAI) Advances AI-Driven Cancer Drug Discov - GuruFocus
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement Dispute | POAI Stock News - GuruFocus
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to - GlobeNewswire
Court Fast-Tracks Renovaro's Lawsuit to Force Predictive Oncology Merger After 50% Stock Jump Drama - Stock Titan
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition | POAI Stock News - GuruFocus
Predictive Oncology harnesses AI for drug discovery - Investing.com
Predictive Oncology moves to leverage biobank using AI - TipRanks
Predictive Oncology harnesses AI for drug discovery By Investing.com - Investing.com Nigeria
Predictive Oncology Inc. Advances AI-Driven Drug Discovery with Extensive Biobank of Tumor Samples - Nasdaq
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewswire
Major AI Breakthrough: How 150,000 Live Tumor Samples Are Revolutionizing Cancer Drug Discovery - Stock Titan
Predictive Oncology issued shareholder letter - TipRanks
Predictive Oncology (POAI) Showcases Recent Achievements and Future Plans | POAI Stock News - GuruFocus
Predictive Oncology Inc. Issues Shareholder Letter Titled, - GuruFocus
Predictive Oncology Expands AI-Driven Platform to Include Biomarker Discovery and Drug Repurposing for Precision Oncology - Nasdaq
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: ... - Bluefield Daily Telegraph
Revolutionary AI Platform Expands into $14.5B Biomarker Market with Game-Changing Cancer Prediction Technology - Stock Titan
Predictive Oncology reports loss, but has "meaningfully expanded the potential" of its AI platform - The Business Journals
Predictive Oncology Inc. Reports Q1 2025 Earnings - TipRanks
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Predictive Oncology (POAI) Sees Significant Revenue Growth in Q1 2025 | POAI Stock News - GuruFocus
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | POAI Stock News - GuruFocus
Predictive Oncology Reports Q1 2025 Financial Results and Corporate Developments - Nasdaq
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies - GlobeNewswire
Predictive Oncology (POAI) Projected to Post Earnings on Tuesday - Defense World
Predictive Oncology Inc Stock (POAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):